

From: (b) (6) (CDC/DDNID/NCCDPHP/OSH)
Sent: Wed, 21 Jul 2021 18:12:35 +0000
To: (b) (6) (CDC/DDPHSIS/CGH/GID); (b) (6) (CDC/DDPHSIS/CGH/DGHT); (b) (6) (CDC/DDID/NCIRD/ID); (b) (6) (CDC/DDID/NCIRD/DVD)
Cc: CDC IMS 2019 NCOV Response EPI TF Policy Deputy; (b) (6) (CDC/DDID/NCEZID/DPEI); (b) (6) (CDC/DDID/NCEZID/DVBD)
Subject: RE: COVID Analytics and Data Modeling -Breakthrough Partnership opp

Humetrix says:

Among the 20 M Medicare beneficiaries in their cohort, a minority of them is also enrolled in Medicaid

They further state:

Approximately 12% of our 20 M population cohort is under age 65, as Medicare covers individuals with disability and end stage renal disease of any age. While the Salus cohort is restricted to the Medicare population, because this population is at higher risk for severe Covid, it has captured to date over 50% of total Covid related hospitalizations and deaths in the US. Also the Medicare population (mainly over age 65) has been the first vaccinated, providing us sizable data for capturing breakthrough infections and for monitoring waning immunity. Last point, our vaccination program monitoring which identifies geographic disparities and ethnic inequities which we have been mapping at the county and zip code level is unique in the country and representative of overall vaccination disparities to help federal efforts and local health departments better target undervaccinated areas.

From: (b) (6) (CDC/DDPHSIS/CGH/GID) <(b) (6)@cdc.gov>
Sent: Wednesday, July 21, 2021 12:56 PM
To: (b) (6) (CDC/DDNID/NCCDPHP/OSH) <(b) (6)@cdc.gov>; (b) (6) (CDC/DDPHSIS/CGH/DGHT) <(b) (6)@cdc.gov>; (b) (6) (CDC/DDID/NCIRD/ID) <(b) (6)@cdc.gov>; (b) (6) (CDC/DDID/NCIRD/DVD) <(b) (6)@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI TF Policy Deputy <eoevent422@cdc.gov>; (b) (6) (CDC/DDID/NCEZID/DPEI) <(b) (6)@cdc.gov>; (b) (6) (CDC/DDID/NCEZID/DVBD) <(b) (6)@cdc.gov>
Subject: RE: COVID Analytics and Data Modeling -Breakthrough Partnership opp

Thanks (b) (6) Do you know if they also have a Medicaid cohort, which would represent a broader age range? I know when we working on TSS for Janssen vaccine, we were working with a group at CDC that had both types of cohorts.

I think it's definitely interesting and would be interested to know about the underlying quality of the data, but looks promising as a potential passive surveillance process going forward.

I don't know if it's worth looping back to the group I was talking about for Janssen TTS about their arrangement for getting that data.

Interested to hear thoughts from (b) (6) and (b) (6)

Thanks

(b) (6)

From: (b) (6) (CDC/DDNID/NCCDPPH/OSH) <(b) (6)@cdc.gov>
Sent: Wednesday, July 21, 2021 11:43 AM
To: (b) (6) (CDC/DDPHSIS/CGH/GID) <(b) (6)@cdc.gov>; (b) (6) (CDC/DDPHSIS/CGH/DGHT) <(b) (6)@cdc.gov>; (b) (6) (CDC/DDID/NCIRD/ID) <(b) (6)@cdc.gov>; (b) (6) (CDC/DDID/NCIRD/DVD) <(b) (6)@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI TF Policy Deputy <eocevent422@cdc.gov>
Subject: FW: COVID Analytics and Data Modeling -Breakthrough Partnership opp

BLUF:

Partners at DoD connected CDC with Humetrix, a commercial group who were able to leverage the SUNet platform and associated data feeds to establish secure enclaves and develop the kinds of analytics that NORTHCOM and others were able to use in their national COVID response (see first attachment).

They are using feeds of Medicare data to identify vaccine breakthrough, identifying areas at risk for COVID (and other pandemics), etc.

As part of their pandemic monitoring for the DoD/JAIC (Joint AI Center), they have been closely monitoring the Covid vaccination program, mapping at the zip code level vaccination disparities and inequities. At the moment they are especially focusing on the monitoring of Covid vaccine breakthrough infections, as well as conducting vaccine safety analysis among the large Salus Medicare population cohort they have defined and which has accounted for more than 50% of total Covid-19 related hospitalizations and deaths in the US in the pre-vaccination phase of the pandemic. At this time they have identified over 80,000 vaccine breakthrough cases among 7 M fully vaccine immunized Medicare beneficiaries, with a 10% hospitalization rate and a 3% death rate

(b)(5)

Please let me know if you'd like to hear more from them.

(b) (6) MS
COVID-19 EPI Task Force Deputy (Policy)
Centers for Disease Control & Prevention
Phone: (b) (6)
Email: (b) (6)@cdc.gov

*Home Office:
Office on Smoking & Health
National Center for Chronic Disease Prevention & Health Promotion
Centers for Disease Control & Prevention*

From: (b) (6) (CDC/DDPHSS/CSELS/DSEPD) <(b) (6)@cdc.gov>
Sent: Saturday, July 17, 2021 7:38 PM
To: (b) (6) <(b) (6)@humetrix.com>; (b) (6) CIV USARMY FUTURES
COMMAND (USA) <(b) (6)@mail.mil>
Cc: (b) (6) <(b) (6)@ecstech.com>; (b) (6) <(b) (6)@humetrix.com>;
(b) (6) (CDC/OD/OADPS) <(b) (6)@cdc.gov>; (b) (6) (CDC/DDID/NCEZID/DVBD)
<(b) (6)@cdc.gov>
Subject: RE: COVID Analytics and Data Modeling - Sustainment Plans

Hello!

Nice to meet everyone and thank you (b) (6) for the introduction. I am headed out of town and will not be available this upcoming week but have added (b) (6) and (b) (6) to see if one of them can find a good POC at Vaccine Task Force to talk with about this as it is a bit beyond my area.

(b) (6) – Do you think you can connect these folks with someone from the COVID-19 vaccine task force (ideally or a person working on breakthrough)?

Thanks and take care!

V/r

(b) (6) MD, MPH, FACPM, (he/him)
COR II, Lean / Six Sigma Blackbelt, Captain USPHS
Director, Preventive Medicine Residency and Fellowship (PMR/F)
Director, Population Health Training In Place Program (PH-TIPP)
Division of Scientific Education and Professional Development
Center for Surveillance, Epidemiology, and Laboratory Services
Centers for Disease Control and Prevention
1600 Clifton Rd. NE, MS V24-5
Atlanta, GA 30329
Work (b) (6)
www.cdc.gov/prevmed (PMR/F)
<https://www.cdc.gov/pophealthtraining/ph-tipp/index.html> (PH-TIPP program)
LinkedIn: <https://www.linkedin.com/in/antonio-neri-md-mph-iss-black-belt/>



From: (b) (6) <(b) (6) @humetrix.com>
Sent: Friday, July 16, 2021 8:33 PM
To: (b) (6) CIV USARMY FUTURES COMMAND (USA) <(b) (6) @mail.mil>; (b) (6) (b) (6) CDC/DDPHSS/CSELS/DSEPD) <(b) (6)@cdc.gov>
Cc: (b) (6) <(b) (6) @ecstech.com>; (b) (6) <(b) (6) @humetrix.com>
Subject: RE: COVID Analytics and Data Modeling - Sustainment Plans

Hi (b) (6) Thank you so much for your introduction to (b) (6)

Hi (b) (6) On behalf of the Humetrix team and our colleague (b) (6) from ECS, we are looking forward to meeting you – thanks to (b) (6) introduction. The best would be to schedule a time for a call/webinar to go over our Salus Covid-19 monitoring platform (also immediately applicable to other infectious disease monitoring, such as influenza). As part of our pandemic monitoring for the DoD/JAIC, we have been closely monitoring the Covid vaccination program, mapping at the zip code level vaccination disparities and inequities. At the moment we are especially focusing on the monitoring of Covid vaccine breakthrough infections, as well as conducting vaccine safety analysis among the large Salus Medicare population cohort we have defined and which has accounted for more than 50% of total Covid-19 related hospitalizations and deaths in the US in the pre-vaccination phase of the pandemic. At this time we have identified over 80,000 vaccine breakthrough cases among 7 M fully vaccine immunized Medicare beneficiaries, with a 10% hospitalization rate and a 3% death rate. Looking forward to further discussing our findings and the capacity of the Salus platform. Let us know when would be a good time to meet- knowing that most of us on the Humetrix side are based in California, and copying (b) (6) in my office to help schedule a time.

Wishing you both a great weekend.

(b) (6)

(b) (6) M.D., M.P.H.
(b) (6)

humetrix

1310 Camino Del Mar, Suite C
Del Mar, CA 92014
Tel: (858) 259-8987, Ext. 210
Fax: (858) 259-9180
Cell: (b) (6)

From: (b) (6) CIV USARMY FUTURES COMMAND (USA) <(b) (6) @mail.mil>
Sent: Thursday, July 15, 2021 10:49 AM
To: (b) (6) (CDC/DDPHSS/CSELS/DSEPD) <(b) (6)@cdc.gov>
Cc: (b) (6) <(b) (6) @ecstech.com>; (b) (6) <(b) (6) @humetrix.com>
Subject: COVID Analytics and Data Modeling - Sustainment Plans

Hi (b) (6) – Great to catch up on the ASPR call yesterday!

Attaching some information (and introducing (b) (6) (b) (6) of Humetrix and (b) (6) who represents ECS) about Project Salus and the COVID data analytic and modeling environment and capabilities that we discussed yesterday.



I'll let Dr. Experton and Jon provide more input. They've done some amazing work!

Best wishes,

(b) (6)

(b) (6)

Science Director

Army Telemedicine & Advanced Technology Research Center